Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction

Introduction: High-strength mesalazine formulations play an important role in providing a convenient option to increase the dose in ulcerative colitis (UC) patients and therefore avoiding the switch to another therapeutic class. Higher doses of mesalazine may be required during periods of remission...

Full description

Bibliographic Details

Published in:	Inflammatory Intestinal Diseases
Main Authors:	Geert D'Haens, Ekaterina Safroneeva, Helen Thorne, Raphaël Laoun
Format:	Article
Language:	English
Published:	Karger Publishers 2023-06-01
Subjects:	ulcerative colitis mesalazine disease extent maintenance high dose faecal calprotectin mayo endoscopic subscore
Online Access:	https://beta.karger.com/Article/FullText/531372